ALX Oncology Holdings Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 83.46 million compared to USD 45.74 million a year ago. Basic loss per share from continuing operations was USD 2.07 compared to USD 2.76 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.94 USD | +0.47% | +18.27% | +13.03% |
Apr. 18 | Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing | MT |
Apr. 10 | ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.03% | 851M | |
-2.85% | 103B | |
+1.58% | 95.28B | |
+1.46% | 22.15B | |
-16.14% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.28% | 16.05B | |
+5.54% | 13.68B | |
+33.04% | 12.17B |
- Stock Market
- Equities
- ALXO Stock
- News ALX Oncology Holdings Inc.
- ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2021